OBJECTIVE: To compare baseline characteristics, treatment frequency, visual acuity (VA), and morphologic outcomes of eyes with >50% of the lesion composed of blood ( @entity13573 group) versus all other eyes (Other group) enrolled in the Comparison of Age-Related @entity1020 Treatments Trials (CATT). DESIGN: Prospective cohort study within a multicenter randomized clinical trial. @entity1 : CATT @entity1 with neovascular @entity1020 ( @entity1020 ). METHODS: Treatment for the study eye was assigned randomly to either ranibizumab or bevacizumab and to 3 different dosing regimens over a 2-year period. Reading center graders evaluated baseline and follow-up morphology in color fundus photographs, @entity941 angiography (FA), and optical coherence tomography (OCT). Masked examiners tested VA. MAIN OUTCOME MEASURES: Morphologic features and VA at 1 and 2 years. RESULTS: The @entity13573 group consisted of 84 of 1185 (7.1%) @entity1 enrolled in CATT. Baseline lesion characteristics differed between groups. In the @entity13573 group, @entity1940 size was smaller (0.73 vs 1.83 disc areas [DA]; P < 0.001), total lesion size was greater (4.55 vs 2.31 DA; P <0.001), total retinal thickness was greater (524 vs 455  m; P  = 0.02), and mean VA was worse (56.0 vs 60.9 letters; P  = 0.002). Increases in mean VA were similar in the @entity13573 and Other groups at 1 year (+9.3 vs  +7.2 letters; P  = 0.22) and at 2 years (9.0 vs 6.1 letters; P  = 0.17). Eyes treated PRN received a similar number of injections in the 2 groups (12.2 vs 13.4; P  =  0.27). Mean lesion size in the @entity13573 group decreased by 1.2 DA at both 1 and 2 years (primarily owing to  resolution of @entity548 ) and increased in the Other group by 0.33 DA at 1 year and 0.91 DA at 2 years (P  <  0.001). Leakage on FA and fluid on OCT were similar between groups at 1 and 2 years. CONCLUSIONS: In CATT, the @entity13573 group had a visual prognosis similar to the Other group. Lesion size decreased markedly through 2 years. Eyes like those enrolled in CATT with neovascular @entity1020 lesions composed of >50% blood can be managed similarly to those with less or no blood.

Outcomes of Eyes with Lesions Composed of  >50% Blood in the Comparison of Age-Related XXXX Treatments Trials (CATT).

@entity1 :: ('9606', 'Species') :: ['patients', 'PARTICIPANTS'] @entity13573 :: ('2596', 'Gene') :: ['B50'] @entity1940 :: ('MESH:D020256', 'Disease') :: ['choroidal neovascularization'] @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage'] @entity941 :: ('MESH:D019793', 'Chemical') :: ['fluorescein'] @entity1020 :: ('MESH:D008268', 'Disease') :: ['Macular Degeneration', 'AMD', 'age-related macular degeneration']
@entity1020 :: (MESH:D008268,Disease) :: ['Macular Degeneration']
